Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: A clue from serum HBsAg levels

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 73-82

  Manesis, Emanuel K ^a   Hadziyannis, Emilia S ^a   Angelopoulou, Olga P ^a   Hadziyannis, Stephanas J ^b  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33847410055     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352:2743-2746.
2. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101-109.
3. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756-763.
4. Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
5. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432-438.
6. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
7. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98:2261-2267.
8. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897.
9. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970; 1(7649):695-698.
10. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120:1828-1853.
11. Maynard M, Parvaz P, Durantel S, et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 2005; 42:279-281.
12. Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998; 5:241-248.
13. Papatheodoridis GV, Manesis EK, Hadziyannis SJ. The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. J Hepatol 2001; 34:306-313.
14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
15. Spiegel MR. Schaum's Mathematical Handbook of Formulas and Tables, 1998; pp270-278. London: McGraw-Hill.
16. Blumberg BS, Alter HJ, Visnich S. A 'new' antigen in leukemia sera. JAMA 1965; 191:541-546.
17. Komoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75:235-239.
18. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 2004; 16:1213-1218.
19. Janssen HLA, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy. Antiviral Res 1994; 23:251-257.
20. Hess G, Gerlich W, Gerken G, Manns M, Hutteroth TH, Meyer zum Buschenfelde K-H. The effect of recombinant α-interferon treatment on serum levels of hepatitis B virus-encoded proteins in man. Hepatology 1987; 7:704-708.
21. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004; 44:1332-1339.
22. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vir Hep Rev 1995; 1:7-36.
23. Werle S, Bowden S, Locarnini S, et al. Reductions in serum hepatitis B surface antigen occur in parallel with reductions in intrahepatic HBV covalently closed circular DNA in chronic hepatitis B patients receiving adefovir dipivoxil. Gastroenterology 2004; 126:A-661.
24. Werle S, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
25. Zoulim F, Mimms L, Floreani M, et al. New assays for quantitative determination of serum markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992; 30:1111-1119.
26. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
27. Pontesilli O, van Nunen AB, van Kiel D, et al. Hepatitis B virus-specific T cell response in chronic hepatitis B patients treated with lamivudine and interferon-alpha. Liver Int 2004; 24:308-315.
28. Melen K, Keskinen P, Lehtonen A, et al. Interferon-induced gene expression and signalling in human hepatoma cell lines. J Hepatol 2000; 33:764-772.
29. Rang A, Bruns M, Heise T, Will H. Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA. J Biol Chem 2002; 277:7645-7647.
30. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and antinflammatory cytokine. Gastroenterology 1997; 112:1017-1021.
31. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284:825-829.
32. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analogue therapy starting with lamivudine. Hepatology 2005; 42:121-129.
33. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42:173-179.
34. Yuen MF, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39:850-855.
35. Vietheer PT, Netter HJ, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol 2005; 79:6570-6573.
36. La'ulu SL, Roberts WL. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 2006; 125:748-751.